mitoxantrone + filgrastim

Mitoxantrone + filgrastim is a combination therapy, typically used as part of multidrug chemotherapy regimens for hematologic malignancies and some solid tumors. **Mitoxantrone** is an anthracenedione antineoplastic agent that intercalates into DNA, causing crosslinks and strand breaks, and inhibits topoisomerase II, leading to cytotoxic effects on rapidly dividing cancer cells. **Filgrastim** is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation and differentiation of neutrophil precursors, helping to reduce the duration and severity of neutropenia induced by chemotherapy. This combination is used in clinical protocols to permit higher or more frequent dosing of cytotoxic drugs by mitigating chemotherapy-induced neutropenia and is frequently included in complex regimens (e.g., CLAG-M: cladribine, cytarabine, filgrastim, mitoxantrone) for relapsed/refractory acute myeloid leukemia and studied with other chemotherapy protocols in metastatic breast cancer[1][2][4][5].